<DOC>
	<DOCNO>NCT00713791</DOCNO>
	<brief_summary>This study design see different formulation ZD4054 ( Zibotentan ) absorb body . As clinical trial , safety tolerability drug evaluate .</brief_summary>
	<brief_title>Relative Bioavailability Study Healthy Male Subjects ZD4054 ( Zibotentan ) Immediate Release Tablets .</brief_title>
	<detailed_description />
	<criteria>Normal rest 12lead ECG normal QTc interval ( &lt; 450 msec ) Negative screen serum hepatitis B surface antigen , hepatitis C antibody Human Immunodeficiency Virus ( HIV ) screen Receipt another new chemical entity 4 month dose study ; participation another study participation noninvasive methodology study drug give within 30 day dose study Risk ( investigator 's opinion ) transmitting , blood body fluid , agent responsible acquire immune deficiency syndrome ( AIDS ) , hepatitis B hepatitis C Judgement investigator , healthy volunteer participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>ZD4054</keyword>
</DOC>